# Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction

> **NCT00712101** · PHASE3 · COMPLETED · sponsor: **University of Leipzig** · enrollment: 1912 (estimated)

## Conditions studied

- ST-elevation Myocardial Infarction

## Interventions

- **DRUG:** abciximab intracoronary
- **DRUG:** abciximab intravenously

## Key facts

- **NCT ID:** NCT00712101
- **Lead sponsor:** University of Leipzig
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 1912 (ESTIMATED)
- **Last updated:** 2011-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00712101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00712101, "Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00712101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*